This article summarized the latest R&D progress of proxalutamide, the Mechanism of Action for proxalutamide, and the drug target R&D trends for proxalutamide.

Recently, Sanofi announced the latest data from the Phase 3 clinical trial named PROTECT for Tzield (teplizumab).

This article summarized the latest R&D progress of moxifloxacin hydrochloride, the Mechanism of Action for moxifloxacin hydrochloride, and the drug target R&D trends for moxifloxacin hydrochloride.

The CGRP receptor, also known as the calcitonin gene-related peptide receptor, plays a crucial role in the human body.

This article summarized the latest R&D progress of mupirocin calcium, the Mechanism of Action for mupirocin calcium, and the drug target R&D trends for mupirocin calcium.

Recently, AstraZeneca announced that the National Medical Products Administration (NMPA) of China has approved C5 complement inhibitor Eculizumab for the treatment of adults.

This article summarized the latest R&D progress of nicardipine hydrochloride, the Mechanism of Action for nicardipine hydrochloride, and the drug target R&D trends for nicardipine hydrochloride.

Amylase is an essential enzyme found in the human body that plays a crucial role in the digestion of carbohydrates.

This article summarized the latest R&D progress of nitrendipine, the Mechanism of Action for nitrendipine, and the drug target R&D trends for nitrendipine.

Recently, UCB announced that the FDA has approved Bimzelx(bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic treatment or phototherapy.

This article summarized the latest R&D progress of osimertinib mesylate, the Mechanism of Action for osimertinib mesylate, and the drug target R&D trends for osimertinib mesylate.

β-lactamase is an enzyme found in the human body that plays a crucial role in the defense against bacterial infections.